Decisions 3rd June 2014


Recent JFG Decisions

 

At the meeting on the 3rd June 2014 the following decisions / changes to the formulary were agreed

 

New Drug Requests

Approved

 

Lisdexamfetamine 

  • Approved for inclusion onto the formulary for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults.

Ibandronic acid

  • Approved for inclusion onto the formulary for the treatment of osteoporosis in post menopausal women if first line alendronate and risedronate are not tolerated. 

Colesevelam

  • Approved for inclusion onto the formulary for the treatment of proven Bile acid malabsorption where colestyramine is either ineffective or not tolerated.  

Rejected/More information needed

 

Oxandrolone

  • Deferred decision.  For adjunctive treatment for nutritional support in paediatric burns.  The guidelines that were submitted with the application need to be signed off by the Bristol Royal Hospital for Children prior to inclusion on the formulary.  

 

Decomissioned policies

 

Bevacizumab

  • Current BNSSG CAF policies reviewed for the treatment of: 

1. for treatment of non-ischaemic central retinal vein occlusion as per criteria based access policy (unlicensed)

2.  for treatment of patients with macular oedema secondary to central or branch retinal vein occlusion as per criteria based access policy (unlicensed)

NICE TA283 has since been published involving the use of Ranibizumab in these indications.  Therefore these policies have now been withdrawn from use.  This decision has been made in conjunction with local ophthalmologists.

 

Shared Care Protocols/TLS Change in Status

 

Riluzole

  • Review of current expired SCP.  Updated SCP accpeted.   

Linaclotide

  • New SCP - Agreed for inclusion onto the formulary for IBS-C who have failed first line therapies. Prescribing data will be reviewed in 6 months.

 

Last updated by: on 01-07-2014 17:25